REG - Oxford Biomedica PLC - 2026 Annual General Meeting notification

Oxford BioMedicaAnnouncement

30/03/2026 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd6813Ya&default-theme=true

RNS Number : 6813Y  Oxford Biomedica PLC  30 March 2026

 

OXB

2026 Annual General Meeting notification

 

Oxford, UK - 30 March 2026: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, gives notice that the Notice of
Annual General Meeting ("AGM") together with a copy of the 2025 Annual report
and accounts are being mailed to shareholders today. These documents are also
available on the "Investors" section of the Group's website at www.oxb.com
(http://www.oxb.com/) .

In accordance with UK Listing rule 6.4.1R, a copy of the Notice of AGM has
been submitted to the Financial Conduct Authority for publication through the
National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . The Company intends
to hold its AGM on 7 May 2026 at its offices at Windrush Court, Transport Way,
Oxford OX4 6LT, commencing at 3:00 p.m.

 

-Ends-

 

Enquiries:

 

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0)
1865 783 000 / E: cosec@oxb.com (mailto:cosec@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development
and manufacturing organisation (CDMO) in cell and gene therapy with a mission
to enable its clients to deliver life changing therapies to patients around
the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class
capabilities range from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK.
It has development and manufacturing facilities across Oxfordshire,
UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn
more at ww (http://www.oxb.com/) w.oxb.com (http://www.oxb.com/)  and follow
us on LinkedIn (https://www.linkedin.com/company/oxford-biomedica)
 and YouTube. (https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAJMMITMTTJBFF



            Copyright 2019 Regulatory News Service, all rights reserved